Efficacy of Huangqi Injection in the Treatment of Hypertensive Nephropathy: A Systematic Review and Meta-Analysis

被引:7
作者
Xu, ZhongChi
Qian, LiChao
Niu, RuGe
Yang, Ying
Liu, ChunLing
Lin, Xin
机构
[1] Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing
[2] Nanjing Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing
基金
中国国家自然科学基金;
关键词
hypertensive nephropathy; Astragalus membranaceus (Fisch.) Bunge; Huangqi injection; systematic review; meta-analysis; BLOOD-PRESSURE CONTROL; DIABETIC-NEPHROPATHY; RENAL-FAILURE; PROTEINURIA; ALBUMINURIA; CREATININE; DISEASE; TARGET;
D O I
10.3389/fmed.2022.838256
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Huangqi injection (HQI) is the extract of Astragalus membranaceus (Fisch.) Bunge, which is widely used in the treatment of a variety of diseases in China. It is supposed to be an important adjuvant therapy for hypertensive nephropathy. Objective: To evaluate the efficacy of HQI combined with antihypertensive drugs in the treatment of hypertensive nephropathy. Materials and Methods: We systematically searched China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), Wanfang Knowledge Service Platform (WanfangData), Chinese Biomedical Database (CBM), EMBASE, PubMed and Cochrane Library from their inception to April 23st, 2021. All studies were independently screened by two auditors according to the inclusion and exclusion criteria. Randomized controlled trials comparing HQI in combination with antihypertensive drugs vs. antihypertensive drugs alone were extracted. Results: The meta-analysis included 15 studies involving 1,483 participants.The effect of HQI combined with antihypertensive drugs is better than that of antihypertensive drugs alone in regulating hypertensive nephropathy for reducing 24-h urinary total protein (24 h UTP) [WMD=-0.29, 95% CI (-0.40, -0.18), P = 0.000], microalbuminuria (mALB) [WMD = -17.04, 95% CI (-23.14, -10.94), P = 0.000], serum creatinine (SCr) [WMD = -40.39, 95% CI (-70.39, -10.39), P = 0.008], systolic blood pressure (SBP) [WMD = -9.50, 95% CI (-14.64, -4.37), P = 0.000], diastolic blood pressure (DBP) [WMD = -4.588, 95% CI (-6.036, -3.140), P = 0.000], cystatin-C (Cys-c) [WMD = -0.854, 95% CI (-0.99, -0.72), P = 0.000], blood urea nitrogen (BUN) [WMD = -4.155, 95% CI (-6.152, -2.157), P = 0.000]. Conclusion: The combination of HQI and antihypertensive drugs is more efficient in improving the related indexes of patients with hypertensive nephropathy than using antihypertensive drugs alone, and a moderate dose of HQI (no more than 30 mL) may benefit more. However, the quality of the methodology is low and the number of samples is small, the results need to be confirmed by more stringent randomized controlled trials.
引用
收藏
页数:17
相关论文
共 54 条
  • [21] Kalaitzidis RG, 2010, CURR VASC PHARMACOL, V8, P604
  • [22] Ke Z, 2013, CHINA MED HERALD, V10, P94
  • [23] Microalbuminuria
    Khosla, Nitin
    Sarafidis, Pantelis A.
    Bakris, George L.
    [J]. CLINICS IN LABORATORY MEDICINE, 2006, 26 (03) : 635 - +
  • [24] Global burden of blood-pressure-related disease, 2001
    Lawes, Carlene M. M.
    Vander Hoorn, Stephen
    Rodgers, Anthony
    [J]. LANCET, 2008, 371 (9623) : 1513 - 1518
  • [25] Danhong Injection for the Treatment of Hypertensive Nephropathy: A Systematic Review and Meta-Analysis
    Li, YiZhuo
    Yan, Shihai
    Qian, Lichao
    Wu, Lihua
    Zheng, Yawei
    Fang, Zhuyuan
    [J]. FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [26] Liu Jing Liu Jing, 2011, Chinese Herbal Medicines, V3, P90
  • [27] Ma J, 1999, J NEPHROLOGY DIALYSI, V4, P315
  • [28] Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.i4086, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299, 10.1016/j.ijsu.2010.02.007, 10.1371/journal.pmed.1000097]
  • [29] Sympathetic hyperactivity in chronic kidney disease: Pathogenesis, clinical relevance, and treatment
    Neumann, J
    Ligtenberg, G
    Klein, II
    Koomans, HA
    Blankestijn, PJ
    [J]. KIDNEY INTERNATIONAL, 2004, 65 (05) : 1568 - 1576
  • [30] Ni Z, 2000, CHIN J NEPHROL, V5, P303